DR-TB Patient Treatment Log Book
|
|
- Magdalen Short
- 5 years ago
- Views:
Transcription
1 REPUBLIC OF KENYA MINISTRY OF HEALTH DR-TB Patient Treatment Log Book Patient Name: Patient Reg. No.: VERSION 2016
2 DR-TB treatment outcome summary Outcome Mark one Date Cured Died Failed Defaulted Transferred out
3
4
5 DR-TB (Category IV) Treatment Card Registration group County: 1 Sub-County: 2 3 Names: DR-TB serial number: Date of Registration: Sub-County DR-TB Registration number: 7 Mobile phone number: Male Age: Female Start date No. (If unknown, put year) HIV information Used second line drugs: Yes HIV testing done: Date of Birth: / / If positive, on ARVs: Yes Patient supporter name: No Results: Pos Physical Address: CD4 count: Initial weight (kg): Height (cm): BMI/BMI for Age/Z score: ART Patient No: Pulmonary Extrapulmonary ARV = Antiretrovirals Both Date started: / / Date Started / / CPT = cotrimoxazole preventive therapy If Extrapulmonary, specify site: TB Symptoms Indicate Regimen: Past Medical History Diabetes mellitus Chronic renal insufficiency Chronic hepatitis or cirrhosis Convulsions, epilepsy Cardiovascular disease Psychiatric history Savere malnutrition Other Other medications used Neg Viral Load: If positive on CPT: Yes/No or N/A Cough Current Medication Other lung diseases Current medication Sputum Fever Shortness of breath Night sweats Wheight loss Tick as applicable Outcome No Don t Know If yes tick as applicable in the table below No ART Regimen Telephone Number: Type of TB Yes Date of test: / / Occupation: Previous tuberculosis treatment episodes New (Primary MDR-TB) Relapse Return after default After failure of first line (Cat 1 or 3) After failure of retreatment (Cat 2) Transfer in Other (previously treated without known outcome status) Nearest school/church/mosque: Sex: Select only one Am Amikacin Km Kanamycin Cm Capreomycin Cfx Ciprofloxacin Ofx Ofx Lfx Levofloxacin Mfx Moxifloxacin Gfx Gatifloxacin Pto Prothionamide Eto Ethionamide Cs Cycloserine PAS Para aminosalicilic acid
6
7 Anthroprometric Measurements Comments Not Done NC FS MN ND
8 SCTLC
9 Month Sputum smear microscopy No. Date* Sample No. Result Sputum smear microscopy Month No. Date* Sample No. Result Culture Month No. Date* Sample No. Result Culture Month No. Date* Sample No. Result Prior** Prior** GENEXPERT Results (tick where applicable) RESISTANT No AFB seen 1-9 AFB per 100 HPF 0 Scanty (Report no of AFB) AFB per 100 HPF AFB per HPF ++ >10 AFB per HPF +++ Notation method for recording cultures No growth reported Fewer than 10 colonies Report no. of colonies colonies + More than 100 colonies ++ Innumerable or confluent growth
10
11
12 AUDIOMETER FOLLOW UP TOOL Month Date FREQUENCY(dbl) Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left 500 1,000 2,000 3,000 4,000 6,000 8,000 COMMENTS
13 RIGHT EAR 8,000 8,000 7,500 7,500 7,000 7,000 6,500 6,500 6,000 6,000 5,500 5,500 Frequency (dbl) Frequency (dbl) LEFT EAR 5,000 4,500 4,000 3,500 5,000 4,500 4,000 3,500 3,000 3,000 2,500 2,500 2,000 2,000 1,500 1,500 1,000 1, Month of Treatment Month of Treatment
14 DR-TB DRUG SIDE EFFECT MONITORING FORM Intensive phase - Adverse effect (indicate grading*) Month/Date Month of treatment Management Date side effect was detected Abdominal pain Constipation Decreased hearing Depression Diarrhea Dizziness Fatigue Fever Headache Joint pain Nausea Psychosis Rash Skin colorization Tinnitus Tremors Vision changes Vomiting Others (list) * Grading: 1 = mild; requiring no intervention 2 = moderate; requiring palliative intervention ** Indicate in the first column the month of treatment that intensive phase ended 3 = severe; requiring change in treatment Outcome
15 DR-TB DRUG SIDE EFFECT MONITORING FORM Intensive phase - Adverse effect (indicate grading*) Month/Date Month of treatment Management Date side effect was detected Abdominal pain Constipation Decreased hearing Depression Diarrhea Dizziness Fatigue Fever Headache Joint pain Nausea Psychosis Rash Skin colorization Tinnitus Tremors Vision changes Vomiting Others (list) * Grading: 1 = mild; requiring no intervention 2 = moderate; requiring palliative intervention ** Indicate in the first column the month of treatment that intensive phase ended 3 = severe; requiring change in treatment Outcome
16 DR-TB DRUG SIDE EFFECT MONITORING FORM Continuation phase - Adverse effect (indicate grading*) Month/Date Month of treatment Management Date side effect was detected Abdominal pain Constipation Decreased hearing Depression Diarrhea Dizziness Fatigue Fever Headache Joint pain Nausea Psychosis Rash Skin colorization Tinnitus Tremors Vision changes Vomiting Others (list) * Grading: 1 = mild; requiring no intervention 2 = moderate; requiring palliative intervention ** Indicate in the first column the month of treatment that intensive phase ended 3 = severe; requiring change in treatment Outcome
17 DR-TB DRUG SIDE EFFECT MONITORING FORM Continuation phase - Adverse effect (indicate grading*) Month/Date Month of treatment Management Date side effect was detected Abdominal pain Constipation Decreased hearing Depression Diarrhea Dizziness Fatigue Fever Headache Joint pain Nausea Psychosis Rash Skin colorization Tinnitus Tremors Vision changes Vomiting Others (list) * Grading: 1 = mild; requiring no intervention 2 = moderate; requiring palliative intervention ** Indicate in the first column the month of treatment that intensive phase ended 3 = severe; requiring change in treatment Outcome
18 DR-TB REGIMEN (Date treatment started and dosage (mg), change of dosage, and ceasation of drugs) Drug INH R Z E High Dose-INH KM AM CM LFX MFX ETO PTO CS Pas BDQ DEL CFZ LZD AMX/CLAV IMP Date treatment started Initial Dosage Date of Dosage revision Adjusted Dose Reason for adjusting dosage Date drug was stopped Reason for stopping the drug
19 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
20 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
21 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
22 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
23 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
24 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
25 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
26 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
27 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
28 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
29 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
30 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
31 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
32 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
33 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
34 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
35 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
36 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
37 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
38 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
39 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
40 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
41 Daily observation of drug intake (One table per month) Reason for missed drug Month Date INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments:
42 Daily observation of drug intake (One table per month) Month Date INH Reason for missed drug R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed Comments: N X Not Supervised Drug not taken
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment
More informationBedaquiline and delamanid Experience of use in children. Bobojon Sharipov Deputy Director of the Republican Tuberculosis Control Centre
Tuberculosis in 2017: Searching for new solutions in the face of new challenges 6th TB Symposium Ministry of Health of the Republic of Belarus, Republican Scientific and Practical Center for Pulmonology
More informationUpdate on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
More informationThe Evaluation of Effectiveness and Safety of Novel Shorter. Treatment Regimens for Multidrug-Resistant Tuberculosis
The Evaluation of Effectiveness and Safety of Novel Shorter Treatment Regimens for Multidrug-Resistant Tuberculosis Operational Research Protocol Template May 2018 A publication of the Global Drug-resistant
More informationHA Convention 2016 : Special Topic Session 3 May 2016
HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationManagement of MDR TB in special situations. Dr Sarabjit Chadha The Union
Management of MDR TB in special situations Dr Sarabjit Chadha The Union MDR TB in special situations Pregnancy Breastfeeding Contraception Renal Insufficiency Diabetes Pregnancy and TB Pregnancy is not
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationTreatment of MDR-TB in high HIV- prevalence settings. Hind Satti, M.D. PIH-Lesotho October 20, 2008
Treatment of MDR-TB in high HIV- prevalence settings Hind Satti, M.D. PIH-Lesotho October 20, 2008 Early outcomes of MDR-TB treatment Retrospective cohort analysis Registered between July 21, 2007 and
More informationSoedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital MDR-TB is a public health crisis 480 000 people developed MDR-TB in
More informationPresented by Leigh Snyman April 2017
Presented by Leigh Snyman April 2017 Overview Definition of Palliative Care Case based discussion Take home messages What is Palliative Care? WHO Definition of Palliative Care: Palliative care is an approach
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More informationDrug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment
Drug Resistant Tuberculosis Self-reporting of Drugrelated Adverse Events During Treatment Introduction This information has been prepared for people with tuberculosis (TB) that is resistant to the commonly
More informationTEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM
TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM PATIENT NAME: DATE OF BIRTH: TVA Physician being seen: Date of Visit: PAST MEDICAL HISTORY HEART PROBLEMS NEUROLOGICAL Congestive Heart Failure
More informationNew TB Medications. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention New TB Medications Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationMEDICINES CATALOG NOVEMBER 2018 GLOBAL DRUG FACILITY (GDF)
NOVEMBER 2018 MEDICINES CATALOG GLOBAL DRUG FACILITY (GDF) Ensuring an uninterrupted supply of quality-assured, affordable tuberculosis (TB) medicines and diagnostics to the world. stoptb.org/gdf Stop
More informationREPORT ON GREEN LIGHT COMMITTEE MONITORING MISSION INDONESIA. January Michael Rich, M.D., M.P.H. Date of mission: January 2017
REPORT ON GREEN LIGHT COMMITTEE MONITORING MISSION INDONESIA Michael Rich, M.D., M.P.H. Date of mission: 15-27 January 2017 January 2017 Acknowledgments The monitoring team would like to express gratitude
More informationShort MDR-TB Regimen, Uzbekistan
Tuberculosis in 2017: Searching for new solutions in the face of new challenges 6th TB Symposium Ministry of Health of the Republic of Belarus, Republican Scientific and Practical Center for Pulmonology
More informationThe shorter regimen for MDR-TB: evidence and pitfalls
The shorter regimen for MDR-TB: evidence and pitfalls Helen Cox 10 November 2017 What is the shortened regimen? Current conventional regimen (SA): Intensive Phase (at least 6 months): PZA / (EMB) / Kana
More informationSURGICAL BREAST PRACTICE NEW PATIENT QUESTIONNAIRE
Patient Name MRN DATE: SURGICAL BREAST PRACTICE NEW PATIENT QUESTIONNAIRE Date of birth Age REASON FOR VISIT Abnormal Mammogram R L please specify Lump/Thickening R L upper lower inner outer Pain R L upper
More informationMultidrug-Resistant Tuberculosis
Pocket Book Multidrug-Resistant Tuberculosis National Clinical Management Training Content 1. Abbreviations 3. Diagnosis of Tuberculosis 4. DS-TB Treatment Monitoring 5. IPT Screening Algorithm 6. ART
More informationUCCM ANISHNAABE POLICE SERVICE EMPLOYMENT VISION REPORT
APPLICANT NAME: UCCM ANISHNAABE POLICE SERVICE EMPLOYMENT VISION REPORT REACTION ACCOM. LIGHT PUPILS EQUAL UNEQUAL FUNDI FIELDS OF VISION COLOUR (TEST USED) WITHOUT GLASSES NEAR FAR WITH GLASSES RIGHT
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationOverview of the Presentation
Overview of the Presentation Definitions(TBCase, MDR-TB & XDR-TB) Global Tuberculosis (TB,HIV/TB,MDR & XDR)Scenario & Trend Risk factor for TB Natural history of TB Types of TB & Trends of Extra Pulmonary
More informationCompassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India
AGORA RESEARCH LETTER Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India To the Editor: Bedaquiline, a mycobacterial ATP synthase inhibitor [1], is the first
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationDOB: / / Please list the names and telephone numbers of the other physicians involved in your care: Name Specialty Phone Address Receive Report (Y/N)
Medical History: Patient: DOB: / / Please list the names and telephone numbers of the other physicians involved in your care: Name Specialty Phone Address Receive Report (Y/N) List the names of prescription
More informationEffectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) M Bonnet, M Bastard, P du Cros, K Atadjan, K Kimenye, S Khurkhumal, A Hayrapetyan, A Telnov, C Hewison, F Varaine
More informationPatient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD
Patient History 1 The Role of Surgery in the Management of TB Reynard McDonald, MD & Paul Bolanowski, MD September 16, 2010 42 y/o AA male was initially diagnosed with pansensitive pulmonary TB in 1986
More informationThe Global Health Impact Index
The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine
More informationDATE OF BIRTH: MELANOMA INTAKE
MELANOMA INTAKE GENERAL INFORMATION How was your first diagnosed? (Check the diagnosis that describes your condition.) Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma Basal Cell Carcinoma Other
More informationGreen Light Committee for the WHO European Region
Green Light Committee for the WHO European Region Country support mission report Ukraine 17 21 September 2018 Country: Ukraine Dates: 17 21 September 2018 Consultants: Content editors: Language editor:
More informationNew and repurposed anti-tb drug introduction and active TB drug-safety monitoring and management
New and repurposed anti-tb drug introduction and active TB drug-safety monitoring and management Alena Skrahina, NTP Belarus WOLFHEZE WORKSHOPS 2017 REACHING OUT To find, treat and cure more TB patients
More informationTuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats
Tuberculosis Facts Below are frequently asked questions about TB, and their answers. If you have additional questions you may contact the City of Ennis Department of Health Services at 972-875-1234 or
More information3855 Burton Street SE Suite A, Grand Rapids, MI Phone Fax Patient Information. Address: City: State: Zip:
3855 Burton Street SE Suite A, Grand Rapids, MI 49546 Phone 616.323.3102 Fax 616.323.3061 Patient Information Patient Name: Preferred Language: Address: City: State: Zip: Home Phone: Cell Phone: Cell Carrier:
More informationGoPrivateMD General Information & History
Date: Date of Birth: Age: Sex: Male Female Address: City: State: Zip: Telephone: Email: PREFFERED PHARMACY NAME & LOCATION: PRIMARY PHYSICIAN: SPECIALISTS: INSURANCE GoPrivateMD will not bill your insurance.
More informationMEDICAL ASSESSMENT PART 1 - SOCIAL HISTORY
Smoking history Alcohol history Never Quit Never Quit PART 2 - MEDICAL HISTORY Date of last colonoscopy? Date of last mammogram? Date of last pap smear? Date of last flu vaccine? Date of last pneumonia
More informationShort Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
More informationPatient Name: Date: Address: Primary Care Physician: Online Website On TV In print On the radio
927 W. Myrtle St. Boise, ID 83702 (208) 947-0100 NEW PATIENT INTAKE Patient Name: Date: Email Address: Primary Care Physician: How did you hear about AVT? (Please mark all that apply) Online Website On
More informationControlling TB in the era of HIV
Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population
More informationBDQ/DLM COMBINATION: FRENCH-LATVIAN EXPERIENCE AND FUTURE PERSPECTIVES LORENZO GUGLIELMETTI RESIST-TB WEBINAR, 5 APRIL 2018
BDQ/DLM COMBINATION: FRENCH-LATVIAN EXPERIENCE AND FUTURE PERSPECTIVES LORENZO GUGLIELMETTI RESIST-TB WEBINAR, 5 APRIL 2018 OUTLINE New TB drugs in France and Latvia Bdq/Dlm: the French-Latvian experience
More informationAnti Tuberculosis Medications: Side Effects & adverse Events
Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,
More informationWorld Health Organization 2010
WHO Library Cataloguing-in-Publication Data: Treatment of tuberculosis: guidelines 4th ed. WHO/HTM/TB/2009.420 1.Antitubercular agents administration and dosage. 2.Tuberculosis, Pulmonary drug therapy.
More informationJoseph S. Weiner, MD, PC Patient History Form
Date: / / NAME: Last First M. I. Age: Sex: q F q M Birthdate: / / What specific questions or goals do you have for this appointment? Please list the names of other clinicians you have seen for this problem:
More informationInformation Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis
Information Note WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis In order to ensure that the upcoming comprehensive revision of WHO policies on treatment
More informationCertainty assessment of patients Effect Certainty Importance. a standardised 9 month shorter MDR-TB regimen. e f
Author(s): STREAM Stage 1 Trial investigators reported for the Guideline Development Group for the WHO treatment guidelines on MDR/RR-TB, 2018 update (6 July 2018) - FINAL RESULTS Question: PICO 1. In
More informationRole of Surgery in the Management of TB. Lee Reichman, MD & Paul Bolanowski, MD
Role of Surgery in the Management of TB Lee Reichman, MD & Paul Bolanowski, MD Patient Background Patient is a 19 year old Bolivian female who immigrated to the US in February 2002 On 3/20/02, she presenting
More informationPatient Background. Role of Surgery in the Management of TB. Patient Background CXR 3/20/02
Patient Background Role of Surgery in the Management of TB Patient is a 19 year old Bolivian female who immigrated to the US in February 2002 On 3/20/02, she presenting to a hospital with complaints of
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationCOMPREHENSIVE NEW PATIENT QUESTIONNAIRE
What brings you in today? What do you prefer to be called (nickname)? Please list all of your medical conditions. 1. 5. 2. 6. 3. 7. 4. 8. What surgical or medical procedures have you had in the past? 1.
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationNew Frontiers: Innovation and Access
8 th Regional TB Symposium - Tashkent, Uzbekistan New Frontiers: Innovation and Access New Guidelines: An Opportunity for National Programmes and Patients: Evidence for new WHO recommendations on MDR-TB
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationWhere is your pain located? Please use the diagram below to indicate where most of your pain is located.
Name: Address: Social Security Number: Email Address: Emergency Contact: Primary Care Physician: Name: Address: Phone Number: Date of Birth: Today's date: Cell Phone Number: Phone #: Referring Physician:
More informationPlease describe, in detail, when the symptoms began:
161 East Mallard Drive, Suite 130, Boise, ID 83706 (208) 947-0100 New Patient Intake Patient Name: Primary Care Physician: Date: Email address: How did you hear about AVT (mark all that apply) Online On
More informationNEUROLOGICAL SURGERY, P.C.
NEUROLOGICAL SURGERY, P.C. PATIENT INFORMATION Name Date of Birth Age Address City Sate NY Zip Home ( ) - Cell ( ) - Work ( ) - Ext: Email Address _ Sex M F Soc. Sec. #: / / Single Married Widowed Separated
More informationPATIENT REGISTRATION
P Account# PATIENT REGISTRATION Please answer all questions completely. PAYMENT IS EXPECTED WHEN SERVICES ARE RENDERED Date New Update Name Date of Birth Male Last First Middle Female Home Address City/State/Zip
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis.
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationPlease have your health insurance card(s), a valid picture ID, and any applicable copayment ready when you check-in.
Please have your health insurance card(s), a valid picture ID, and any applicable copayment ready when you check-in. We have enclosed a questionnaire for you to complete and bring to the visit. Please
More informationDebbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas
Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION
More informationCECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)
IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:
More informationendtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3
endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3 Notice This guide is a draft version designed to give guidance to the endtb Project site on the use of new TB
More informationCaspian Acupuncture -- Health History Form Anita Tayyebi EAMP, LAc. 652 SW 150 th St Burien WA 98166
Frist Name Last: Date Phone (H) (C) (W) E-mail Address City State Zip Age DOB Place of Birth _ Marital/Partnership Status Preferred Gender Pronoun _ Profession Family Physician Telephone # Referred By
More informationendtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3
endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3 Notice This guide is designed to give guidance to the endtb Project site on the use of new TB drugs bedaquiline
More informationScreening and Treatment Recommendations for Persons Exposed to MDR TB
Screening and Treatment Recommendations for Persons Exposed to MDR TB Although all persons at increased risk of tuberculosis (TB) infection should be screened for TB infection per USPTF/CDC guidelines
More informationSilver Child Development Center New Patient Questionnaire. Relation (circle) Biological Mother Stepmother Adoptive Mother
Silver Child Development Center New Patient Questionnaire Today s Date Mother s Name First Last Date of Birth Relation (circle) Biological Mother Stepmother Adoptive Mother Foster Mother Other Father s
More informationMINISTRY OF HEALTH, MALAWI. GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF MANAGEMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS IN MALAWI
MINISTRY OF HEALTH, MALAWI. GOVERNMENT OF MALAWI GUIDELINES FOR THE PROGRAMMATIC MINISTRY OF HEALTH MANAGEMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS IN MALAWI GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT
More informationManaging the Patients Response to TB Treatment
Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has
More informationNew Patient Documentation. Name: (Last) (First) (Middle) Address: (Street) (Apt#) (City) (State) (Zip) Home Phone: ( ) Cell: ( ) Work: ( )
New Patient Documentation Name: (Last) (First) (Middle) Address: (Street) (Apt#) (City) (State) (Zip) Home Phone: ( ) Cell: ( ) Work: ( ) Age: Birthdate: E Email: Social: Sex: Male Female Height: Weight:
More informationPatient Intake Form for Acupuncture Treatment at Infinite Healing
Section A: Your Information Patient Intake Form for Acupuncture Treatment at Infinite Healing Last Name: First Name: Middle Initial: Mailing Address: _ City: Postal Code: E-mail: Birth date: M D YR Age:
More informationTuberculosis in Chicago 2007
City of Chicago Communicable Disease Information Department of Public Health Richard M. Daley, Mayor May 2008 Terry Mason, MD, FACS, Commissioner www.cityofchicago.org/health/ West Side Center For Disease
More informationLinezolid in the Treatment of Multidrug-Resistant Tuberculosis
MAJOR ARTICLE Linezolid in the Treatment of Multidrug-Resistant Tuberculosis G. F. Schecter, 1 C. Scott, 1,3 L. True, 1 A. Raftery, 2 J. Flood, 1 and S. Mase 3 1 Tuberculosis Control Branch, Division of
More informationNEW PATIENT REGISTRATION FORM
NEW PATIENT REGISTRATION FORM (Please Print) PATIENT INFORMATION Patient s last name: First: Middle: Ethnicity: Hispanic Non-Hispanic Mr. Mrs. Ms. Miss Is this your legal name? If not, what is your legal
More informationPULMONARY CARE OF CENTRAL FLORIDA, P.A. Date: / /
PULMONARY CARE OF CENTRAL FLORIDA, P.A. Date: / / Patient Name Age DOB: / / Family Physician Referring Physician Telephone Number Telephone Number Pharmacy: Phone: Fax: MEDICAL HISTORY 1. What is your
More informationColumbus Oncology and Hematology Associates 810 Jasonway Ave. Columbus, OH 43214, Ph: , Fax:
Columbus Oncology and Hematology Associates 810 Jasonway Ave. Columbus, OH 43214, www.coainc.cc Ph: 614.442.3130, Fax: 614.442.3145 Name (Last, First, Middle) Birth Date Age Social Security # Appointment
More informationBahl & Bahl Medical Associates PATIENT MEDICAL HISTORY
Bahl & Bahl Medical Associates PATIENT MEDICAL HISTORY NAME: _ DATE: Please complete the following questionnaire as completely as possible. 1. MEDICAL HISTORY Please list all current and prior health problems,
More informationAllina Health United Lung and Sleep Clinic
Medical History Form Date Allina Health United Lung and Sleep Clinic Name Last First MI Date of birth What lung problem do you want us to help you with: Who is your primary care provider? Social History
More informationMCKAY UROLOGY LINCOLNTON OFFICE PATIENT HISTORY FORM
Patient name: MRN #: Current Medications (prescription and over the counter medications including vitamins, herbs, aspirin, antacids, injectables, hormones and birth control medication) If you brought
More informationendtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.2
endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.2 Notice This guide is a draft version designed to give guidance to the endtb Project site on the use of new TB
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationREDROCK MEDICAL GROUP INITIAL HISTORY AND PHYSICAL
REDROCK MEDICAL GROUP INITIAL HISTORY AND PHYSICAL NAME: BIRTH DATE: AGE: SEX: M F OCCUPATION: RACE: WHO REFERRED YOU TO OUR OFFICE? _ WHAT IS YOUR MAIN COMPLAINT? HOW LONG HAS THIS BEEN A PROBLEM? IS
More informationNATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis
NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis Patients registered during quarter* of 20 Name of area No.# Name of the Reporter Signature:
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationBedaquiline and delamanid combination as part of a MDR-TB treatment regimen: Current evidence and practices
Bedaquiline and delamanid combination as part of a MDR-TB treatment regimen: Current evidence and practices Cathy Hewison, Médecins Sans Frontières RESIST-TB 5 th April 2018 Outline Current recommendations
More informationChapter 5 Treatment. 5.1 First-Line Antituberculous Treatment
Chapter 5 Treatment Abstract In this chapter the treatment of drug sensitive and drug resistant TB and timing of antiretroviral treatment for HIV infected patients will be reviewed. Emphasis is placed
More informationRoll-out of new TB drugs and short-course regimens in the Kyrgyz Republic
Treating Patient, Not Disease: People-Centered Approach 1-2 March, 2018, BISHKEK, KYRGYZSTAN Roll-out of new TB drugs and short-course regimens in the Kyrgyz Republic A. Kadyrov, PhD in Medicine Director
More informationNEW PATIENT REGISTRATION PLEASE COMPLETE ALL ITEMS ON EACH PAGE. Name (Last, First, M.I.) Address. City State Zip Code. Phone ( ) Work ( ) Cell ( )
NEW PATIENT REGISTRATION PLEASE COMPLETE ALL ITEMS ON EACH PAGE Date Name (Last, First, M.I.) Address City State Zip Code Phone ( ) Work ( ) Cell ( ) Date of Birth Age Marital Status SSN Employer Employer
More informationAPSR RESPIRATORY UPDATES
Volume 11 Issue 1 Newsletter Date: January 2019 APSR EDUCATION PUBLICATION Inside this issue: Updates on Treatment in Drug Resistant Tuberculosis World TB Day 2018: the challenge of drug resistant tuberculosis
More informationMonica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale
Randomized Trial of lsoniazid as Secondary Prophylaxis for Prevention of Recurrent Pulmonary Tuberculosis in HIV-positive Patients After One Episode of Tuberculosis Monica Manandhar A. Study Purpose and
More informationTB: Siriraj Internal Medicine Board Review 2018
TB: Siriraj Internal Medicine Board Review 2018 Nitipatana Chierakul Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj medical School, Bangkok, THAILAND TB-HIV 8 % Achievement
More informationTB in Prisons and Jails Albuquerque, New Mexico November 28, 2012
TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following
More informationStudy of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan
Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza
More informationTB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects
TB Nurse Case Management San Antonio, TX April 1 3, 2014 TB Medications and Adverse Effects Debbie Onofre RN, BSN Nurse Consultant/ Nurse Educator Heartland National TB Center April 1, 2014 Debbie Onofre,
More informationCHRISTOPHER BROWN D.O. - TRADITIONAL OSTEOPATHY
CHRISTOPHER BROWN D.O. - TRADITIONAL OSTEOPATHY REGISTRATION PAGE Date: Name: Tel: 510-526-5256 (Albany) 415-334-1010 (San Francisco) Fax: 510-526-5547 christopherbrowndo@gmail.com DOB: Age: Sex: Address:
More information